Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The adrenergic alpha 2 receptor is a GPCR with three main subtypes that mediate inhibition of adenylyl cyclase via Gi proteins—leading to reduced cAMP levels—and play crucial roles both centrally (sedation/cognition/neurotransmission) and peripherally (vascular tone/blood pressure). Clinically important agonists target these receptors for conditions ranging from hypertension to ADHD or procedural sedation.
Agonists bind to the α2-adrenergic receptor, activating Gi proteins. This leads to inhibition of adenylyl cyclase, decreased cAMP levels, hyperpolarization of neurons, and reduced neurotransmitter release.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adrenergic alpha-2 receptor (α2-adrenergic receptor).